Key result
Gram-negative LVAD infections show high morbidity, with ~35% infection-related mortality despite prolonged antibiotic regimens.
Why the study?
Gram-negative bacterial LVAD infections pose significant challenges due to antimicrobial resistance and high relapse rates, while standardized treatment guidelines remain limited.
What are the current antimicrobial strategies, treatment durations, and clinical outcomes for patients with Gram-negative bacterial LVAD infections?
Systematic Review (n=25)
Yes
What are the current antimicrobial strategies, treatment durations, and clinical outcomes for patients with Gram-negative bacterial LVAD infections?
Answers are grounded in this paper and cite their sources.
This systematic review demonstrates that antibiotic treatment for Gram-negative LVAD infections varies widely by infection depth and location, underscoring the urgent need for standardized, evidence-based protocols.
Background: Gram-negative bacterial left ventricular assist device (LVAD) infections pose significant challenges due to antimicrobial resistance and high relapse rates. Moreover, current standardized treatment guidelines remain limited. Thus, this study aimed to evaluate current antimicrobial strategies for Gram-negative bacterial LVAD infections, highlight treatment trends, and examine outcomes to inform clinical decision-making. Methods: A systematic review was conducted in accordance with the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies were included if they reported antibiotic regimens for Gram-negative LVAD-specific infections and the clinical outcomes of these infections. Antibiotic regimens, associated management strategies, and clinical outcomes were summarized by infection location. Results: A total of 15 studies were included, reporting 25 cases of Gram-negative LVAD-specific infections and 28 identified Gram-negative pathogens. Most cases involved superficial or deep driveline/exit-site/pocket infections (16/25, 64.0%), whereas pump/cannula infections and device-specific bloodstream infections occurred in 3/25 (12.0%) and 6/25 (24.0%) patients, respectively. Antibiotic strategies varied widely in both selection and duration. Superficial driveline and exit-site infections were treated with a median of 14 days of antibiotics (interquartile range (IQR), 14-21.5; range, 7-49), whereas deep driveline/pocket infections required longer treatment with a median of 42 days (IQR, 31.5-42; range, 14-42). Pump/cannula and bloodstream infections often required prolonged therapy, suppressive treatment, and/or major surgical intervention. Conclusions: The treatment of Gram-negative bacterial LVAD infections remains highly variable and poorly characterized due to the limited number of reported cases, making it difficult to establish evidence-based clinical recommendations. This highlights the urgent need for further research to establish evidence-based treatment protocols and improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Jahangiri et al. (2026) conducted a systematic review in Gram-negative bacterial left ventricular assist device (LVAD)-specific infections (n=25). Antibiotic treatment for Gram-negative LVAD-specific infections was evaluated on Clinical outcomes including relapse, surgical source control, suppressive therapy, and infection-related mortality across LVAD infection locations. Antibiotic regimens for Gram-negative LVAD infections lasted a median of 14 days for superficial and 42 days for deep/bloodstream infections, with 32.0% relapse and 35.0% infection-related mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: